Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2017-10-04 M&A Activity
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Ligand Pharmaceuticals. It announces the entry into a material definitive agreement, specifically a merger agreement to acquire Crystal Bioscience, Inc. The document details the terms of the merger, including consideration, conditions, and forward-looking statements. It also includes exhibits such as the merger agreement and a press release. The content is focused on merger activity and related disclosures rather than a full financial report, earnings release, or other categories. Therefore, the document fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2017-10-04 English
PRIMARY DOCUMENT
Director's Dealing
2017-09-07 English
FORM 4
Director's Dealing
2017-08-25 English
FORM 4
Director's Dealing
2017-08-22 English
FORM 3
Director's Dealing
2017-08-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 18, 2017, reporting the appointment of a new director, Nancy Ryan Gray, to the Board of Directors of Ligand Pharmaceuticals. The key section is Item 5.02, which specifically addresses the departure or appointment of directors or certain officers. The document includes details about Dr. Gray's background, compensation, and the fact that this appointment was recommended by the Nominating and Corporate Governance Committee. There is no financial data or report content; rather, it is an announcement of a management/board change. Therefore, the document fits the category of Board/Management Information (MANG). The document length (5685 characters) and content confirm it is not a brief announcement but a full current report on this management change.
2017-08-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.